The quarter itself is a non-event for a pre-revenue biotech — the stock will trade on pipeline catalysts, not financials. Key near-term catalysts: obexelimab BLA submission (Q2 2026), EULAR presentation (June 4), and SunStone SLE topline (Q4 2026). The $718.5M cash runway into 2029 removes near-term financing risk. Monitor for any FDA communication delays or adverse SunStone results.
Price Chart
Executive Summary
Zenas BioPharma reported Q1 2026 results: net loss widened to $81.0M from $33.6M a year ago, with zero revenue vs $10M in Q1 2025, driven by R&D and G&A cost increases as the company advances its pipeline. The board also saw the departure of Tomas Kiselak, who did not stand for re-election. The company raised $419M in gross proceeds YTD from convertible notes, common stock offerings, and ATM sales, extending cash runway into 2029. Key catalysts remain on track: obexelimab BLA submission to the FDA this quarter, SunStone SLE topline results in Q4 2026, and ZB021 Phase 1 data by year-end.
Key Financial Metrics
Key Facts
- Net loss of $81.0M for Q1 2026 vs $33.6M in Q1 2025
- Zero revenue in Q1 2026 vs $10.0M license revenue in Q1 2025
- Cash, cash equivalents and investments of $718.5M as of March 31, 2026
- Raised $419M YTD from convertible notes, common stock offerings, and ATM
- Obexelimab BLA submission to FDA on track for Q2 2026
- SunStone SLE trial enrollment complete; topline results expected Q4 2026
- First subject dosed in ZB021 Phase 1 trial; initial data expected by year-end 2026
- Director Tomas Kiselak did not stand for re-election at the 2026 Annual Meeting
- Stockholders ratified Ernst & Young as independent auditor for FY2026
Financial Impact
Net loss increased by $47.4M YoY to $81.0M; revenue dropped to $0 from $10M; cash position doubled to $718.5M
Risk Factors
- Obexelimab BLA submission or FDA acceptance could be delayed
- SunStone SLE trial topline results in Q4 2026 could be negative
- Orelabrutinib Phase 3 MS trials may fail to meet endpoints
- Dependence on single CMO (WuXi Biologics) in China introduces supply chain risk
- Significant debt ($193.6M convertible notes, $72.1M term loan) adds financial leverage
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-059700 |
| Document: tm2614295d1_8k.htm | 0001104659-26-059700 |
| Document: 0001104659-26-059700-index-headers.html | 0001104659-26-059700 |
| Document: 0001104659-26-059700-index.html | 0001104659-26-059700 |
| Document: 0001104659-26-059700.txt | 0001104659-26-059700 |
| 8-K Data (Synthetic) | 0001104659-26-059700 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G | $27.09 | awaiting T+60 | — | $27.30 (+0.78%) |
Oct 16, 2026 11d ago | Press Release | $26.71 | awaiting T+60 | — | $27.30 (+2.21%) |
Oct 13, 2026 14d ago | 8-K | $25.16 | awaiting T+60 | — | $27.30 (+8.51%) |
Sep 22, 2026 5w ago | Press Release | $33.05 | awaiting T+60 | — | $27.30 (−17.40%) |
Sep 18, 2026 5w ago | Press Release | $32.55 | awaiting T+60 | — | $27.30 (−16.13%) |
Sep 11, 2026 6w ago | S-3ASR | $31.91 | awaiting T+60 | — | $27.30 (−14.45%) |
May 28, 2026 21w ago | Press Release | $18.56 $32.29 | ▲ +73.98% | ▲ +72.24% | $27.30 (+47.09%) |
May 19, 2026 23w ago | Press Release | $17.84 $29.20 | ▲ +63.68% | ▲ +57.39% | $27.30 (+53.03%) |
May 13, 2026 23w ago | Press Release | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.30 (+36.98%) |
May 13, 2026 23w ago | 8-K | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.30 (+36.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers